Skip to main content
. 2022 Jul 15;12(7):3067–3082.

Figure 4.

Figure 4

PI3K inhibitors with or without trastuzumab induce down-regulation of phospho-AKT, phospho-S6, and apoptosis. A. HCC1954, UACC893, and HCC1569 cells were treated with the indicated agents. Lysates were collected 24 hours after treatment. The cells treated with alpelisib and alpelisib plus trastuzumab showed down-regulation of phospho-AKT and phospho-S6. Within the same groups, overexpression of cleaved-PARP and cleaved-caspase 3 were observed. The control and trastuzumab groups did not show the above protein cleavage. B. Three breast cancer cell lines were treated with the indicated agents. GDC-0077 with or without trastuzumab contributed to down-regulation of phospho-AKT and phospho-S6, and up-regulation of cleaved-PARP and cleaved-caspase 3, whereas the other two groups did not. The trastuzumab concentration was 2 μg/mL. The alpelisib concentrations were 2, 0.5, and 4 μM for HCC1954, UACC893, and HCC1569 cells, respectively. The GDC-0077 concentrations were 0.8, 0.4, and 3.2 μM for HCC1954, UACC893, and HCC1569 cells, respectively. Numbers under each western blot represent the intensity of the protein relative to the control.